2-(1,3-benzothiazol-2-ylamino)-4-(methylthio)butanoic acid, also known as **BTSA**, is a synthetic compound that acts as a **potent and selective inhibitor of the enzyme methionine adenosyltransferase (MAT)**.
**What is Methionine Adenosyltransferase (MAT)?**
MAT is a crucial enzyme involved in the biosynthesis of S-adenosyl methionine (SAM), a universal methyl donor that plays a critical role in numerous metabolic pathways. SAM is essential for various processes like:
* **DNA methylation**
* **Protein methylation**
* **Neurotransmitter synthesis**
* **Lipid metabolism**
**Why is BTSA Important for Research?**
**1. Understanding the Role of MAT:**
* BTSA, as a specific inhibitor of MAT, allows researchers to study the role of MAT and SAM in various biological processes. By inhibiting MAT activity, researchers can investigate the consequences of decreased SAM levels and gain insights into the regulatory mechanisms of these pathways.
**2. Developing New Therapeutics:**
* Given the diverse functions of SAM, dysregulation of MAT activity is linked to several diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases.
* BTSA, as a selective MAT inhibitor, holds therapeutic potential for these conditions by modulating SAM levels and their associated metabolic pathways.
* Researchers are exploring the use of BTSA and its derivatives as potential drugs for specific conditions.
**3. Studying Cellular Metabolism:**
* BTSA can be a valuable tool for investigating the metabolic pathways that rely on SAM.
* Researchers can use BTSA to study the effects of altered SAM levels on various cellular processes, including cell growth, differentiation, and apoptosis.
**4. Potential for Drug Development:**
* The selectivity and potency of BTSA make it an attractive starting point for developing novel drugs targeting MAT activity.
* Researchers can modify the structure of BTSA to improve its pharmacokinetic properties and optimize its therapeutic potential.
**In summary, BTSA is a valuable research tool for understanding the role of MAT in cellular processes, developing new therapeutic strategies for diseases linked to SAM dysregulation, and investigating the intricacies of cellular metabolism.**
ID Source | ID |
---|---|
PubMed CID | 651739 |
CHEMBL ID | 1453118 |
CHEBI ID | 105801 |
SCHEMBL ID | 23273787 |
Synonym |
---|
OPREA1_595965 |
smr000001304 |
BAS 00280985 |
MLS000031314 |
2-(benzothiazol-2-ylamino)-4-methylsulfanyl-butyric acid |
OPREA1_090519 |
CHEBI:105801 |
AKOS000301332 |
2-(1,3-benzothiazol-2-ylamino)-4-methylsulfanylbutanoic acid |
436810-97-8 |
A826394 |
2-(benzo[d]thiazol-2-ylamino)-4-(methylthio)butanoic acid |
2-(benzothiazol-2-ylamino)-4-methylsulfanylbutyric acid |
HMS2356H11 |
FT-0644676 |
2-(benzothiazol-2-ylamino)-4-methylsulfanyl- butyric acid |
AKOS024302430 |
2-(benzothiazol-2-ylamino)-4-methylsulfanylbutyricacid |
CHEMBL1453118 |
Q27183582 |
2-(1,3-benzothiazol-2-ylamino)-4-(methylthio)butanoic acid |
DTXSID10349533 |
SR-01000326221-1 |
sr-01000326221 |
SCHEMBL23273787 |
2-[(1,3-benzothiazol-2-yl)amino]-4-(methylsulfanyl)butanoic acid |
Class | Description |
---|---|
methionine derivative | An amino acid derivative resulting from reaction of methionine at the amino group or the carboxy group, or from the replacement of any hydrogen of methionine by a heteroatom. The definition normally excludes peptides containing methionine residues. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 4.4668 | 0.0447 | 17.8581 | 100.0000 | AID485294 |
aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 39.8107 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
P53 | Homo sapiens (human) | Potency | 44.6684 | 0.0731 | 9.6858 | 31.6228 | AID504706 |
Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 7.0795 | 1.9953 | 25.5327 | 50.1187 | AID624288 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
negative regulation of inflammatory response to antigenic stimulus | Guanine nucleotide-binding protein G | Homo sapiens (human) |
renal water homeostasis | Guanine nucleotide-binding protein G | Homo sapiens (human) |
G protein-coupled receptor signaling pathway | Guanine nucleotide-binding protein G | Homo sapiens (human) |
regulation of insulin secretion | Guanine nucleotide-binding protein G | Homo sapiens (human) |
cellular response to glucagon stimulus | Guanine nucleotide-binding protein G | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Process | via Protein(s) | Taxonomy |
---|---|---|
G protein activity | Guanine nucleotide-binding protein G | Homo sapiens (human) |
adenylate cyclase activator activity | Guanine nucleotide-binding protein G | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Process | via Protein(s) | Taxonomy |
---|---|---|
plasma membrane | Guanine nucleotide-binding protein G | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |